LEUVAS THERAPEUTICS

LEUVAS THERAPEUTICS is a recently established biopharmaceutical company is developing therapeutics that block leukocyte-vascular interactions (LVI) addressing clear unmet medical needs in large markets with potential for both first-in-class and best-in-class therapeutics addressing. They are leveraging their recent discoveries that dysfunctional endothelium, inflammatory vascular changes, and leukocyte-vascular interactions (LVI) underlie disease pathogenesis in epilepsy, Alzheimer’s Disease and other common neurodegenerative diseases.